Show results for
Refine by
Liquid Biopsy Suppliers Serving Austria
54 companies found
based inJesi (AN), ITALY
Diatech Pharmacogenetics is the Italian leader in the development, production and commercialisation of pharmacogenetics tests for cancer precision medicine. Founded in 1996, Diatech Pharmacogenetics has sustained constant organic growth over the ...
based inCambridge, UNITED KINGDOM
Owlstone Medical is developing a breathalyzer for disease. With a goal to find ways to improve non-invasive diagnostics for respiratory diseases, liver diseases, cancer, digestive health and other conditions. Our mission is to save 100,000 lives and ...
based inSan Diego, CALIFORNIA (USA)
Nucleix is a liquid biopsy company revolutionizing cancer treatment with earlier disease detection, at a time when intervention can bring the greatest impact for patients. Leveraging PCR-based epigenetics, our pioneering testing approach uses ...
Liquid biopsies are a new powerful tool in cancer diagnostics that is transforming patient healthcare. Body fluids such as blood or urine are obtained from the patient and analyzed for the presence of circulating ...
based inValladolid, SPAIN
Founded in 2010, AMADIX is a leading molecular diagnostics company, focused on liquid biopsy, developing innovative diagnostic tests for early cancer detection in blood. Our mission is to extend people’s lives by developing disruptive technologies ...
It can also be used as a tool for a high-risk screening population in combination with Low Dose Computed Tomography (LDCT). DiagnoLung identifies and measures proteins which are differentially expressed in blood samples of individuals with Lung ...
based inDaejeon, SOUTH KOREA
PANAGENE have been supplying Peptide Nucleic Acid (PNA) worldwide and exclusively since 2006 based on our unique invention of efficient synthesis of PNA with high purity, and nowadays we are possessing the best knowledge on PNA and the largest ...
NRAS mutation is found in several cancers such as melanoma (13~25%), colorectal cancer (1~6%), lung cancer (1%), thyroid cancer (7%) and hepatocellular carcinoma (10%). It is know that the drug response against colorectal cancer medicine such as ...
based inBoston, MASSACHUSETTS (USA)
SOPHiA GENETICS is the creator of a global data-sharing network – we work with customers from over 790 institutions in over 70 countries. Our network advances data-driven medicine to improve health outcomes and economics worldwide. We offer a ...
Deeper genomic insights, fewer missed opportunities. CGP enables clinical researchers to identify actionable variants and biomarkers across hundreds of genes using a single solution. The SOPHiA DDMTM Platform offers decentralized, in-house next ...
based inHuntsville, ALABAMA (USA)
Kailos Genetics provides consumers access to affordable physician-ordered genetic tests. It is our mission to help people take control of their health and make more informed decisions. The Kailos test is an easily accessible genetic test catered to ...
The Iota assay detects methylation differences in a person’s blood sample, the superior choice for early disease detection. The process of detecting these changes is called a methylated liquid biopsy and it ...
based inHeidelberg, GERMANY
Hummingbird is harnessing the predictive power of blood-borne miRNAs to provide insights into human health and disease. Analysis of miRNAs with Hummingbird’s platform holds the potential for early disease detection, disease-specific prognostics, ...
MiRNAs are small, highly conserved, non-coding RNAs playing crucial roles in the regulation of virtually all aspects of living ...
based inGuro-gu, SOUTH KOREA
We provide diagnostic solutions throughout the cancer treatment cycle from early cancer diagnosis to prognostic and companion diagnostics as well as postoperative monitoring. Diagnose cancer as early as possible, when the disease is easiest to ...
These tests detect DNA mutations by analyzing certain genes extracted from the patient's blood and tumor samples based on ddPCR platform which is optimized for companion diagnostics. They select patients who benefit the effectiveness of cancer ...
based inAlameda, CALIFORNIA (USA)
Fluxion delivers advanced solutions that transform complex cell-based and cell-free assays. Leading labs across the globe rely on Fluxion's instruments, kits, and lab services to research novel biology, accelerate drug discovery, and tailor ...
Fluxion provides analytical services for a diverse range of liquid biopsy and CTC applications. Our Lab Services programs enables you to get results quickly and efficiently using Fluxion’s state-of-the-art ...
based inWaltham, MASSACHUSETTS (USA)
Exosome Diagnostics, Inc. is commercializing minimally invasive molecular diagnostics in blood and urine to enable doctors to select optimal therapies for cancer and other diseases. Exosomes are lipid bilayer covered microvesicles shed by solid ...
The only exosome-based test that provides unique, actionable intelligence to help you decide if biopsy is necessary; independent of PSA and other standard of care (SOC) features. Connect with a representative in your area for more information ...
based inSeoul, SOUTH KOREA
We detect and analyze genomic profile of tumor DNA with a single draw of blood. With this comprehensive profile, we provide personalized and optimized analysis information that can be utilized in therapy selection and monitoring. Ultimately, we ...
Tissue specimens are either from surgical resections or biopsies which may raise the risk of bleeding, and infection and further require recovery from the procedure. Genomic profiling of tissue samples provides a single point in space and time which ...
based inParis Cedex 06, FRANCE
We develop and commercialize patented, disruptive liquid biopsy tests – innovative blood tests in oncology – based on a unique cell isolation technology called ISET (Isolation by SizE of Tumor cells) and cyto-molecular profiling of Circulating Tumor ...
Cancer is the second cause of death, accounting for nearly 9 million deaths in 2017 all over the world. In 2019, 1,762,450 new cancer cases and 606,880 cancer deaths are projected to occur in the United States. It is estimated that metastasis is the ...
based inAuburn, ALASKA (USA)
SiO2 Materials Science is focused on three core segments: Pharmaceuticals, Molecular Diagnostics, and Consumer Healthcare. In the pharma segment, we solve more than 30 problems including some of the most challenging related to drug stability, drug ...
based inSeoul, SOUTH KOREA
We Develop Next-Generation In Vitro Diagnostic System and Enabling Technologies For Liquid Biopsy. Curiosis’ expert team of scientists and engineers are dedicated to provide the best research and diagnostics solution with the core technologies of ...
based inFrederick, MARYLAND (USA)
In 2019, ProMedDx and GLAS Bio were acquired by Precision for Medicine, part of Precision Medicine Group. This new combination significantly bolstered the selection, scientific prowess and solutions available to customers from a single partner. With ...
Experienced global network of principal investigators, labs, and logistics experts available to source tissues for your research program. ...
based inSint-Denijs Westrem, BELGIUM
We are a commercial stage medical device company developing the alfapump® platform for the treatment of fluid overload in liver disease, malignant ascites and heart failure where diuretics are no longer effective. The alfapump®, is a fully ...
Ascites is also a common complication of certain late-stage cancers due to fluid build-up in the peritoneal cavity from a number of causes including draining of the lymph system. While life expectancy for many cancer patients with malignant ascites ...
based inWest Lafayette, INDIANA (USA)
Tymora Analytical Operations provides diagnostic development and exosome proteomics contract services and products for improved cancer research. Tymora’s primary goal is to enable the shift from tissue to liquid biopsy. Our new technologies allow ...
based inPalo Alto, CALIFORNIA (USA)
Lucence is a precision oncology company committed to bringing clarity to cancer care. Lucence makes ultrasensitive non-invasive liquid biopsy tests to provide doctors and their patients life-changing information to enable earlier detection and ...
AmpliMark is the foundational technology behind Lucence’s liquid biopsy tests. AmpliMark uses unique molecular barcodes in this error-correction technology. It is designed to improve detection of multiple ...
based inNew Taipei City, TAIWAN
Established 2011 in Taiwan's aspiring capital Taipei, Zinexts Life Science has become a leading Biotechnology Company that is designing, developing and manufacturing a wide array of reliable, user friendly and cost effective Molecular Biology ...